Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ BACE2 Chimeric Recombinant Mouse Monoclonal Antibody (1/ 9)
Mouse Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA547981
Description
BACE2 Chimeric Recombinant Monoclonal Antibody for Western Blot, ICC/IF, IHC
BACE2 or Beta Secretase 2 is responsible for the proteolytic processing of the amyloid precursor protein (APP). BACE2 cleaves APP between residues 690 and 691. This cleavage leads to the generation and extracellular release of beta-cleaved soluble APP. BACE2 is also know to cleave APP between residues 671 and 672. Accumulation of APP is a signature of Alzheimer disease and frequent complication of adult Down syndrome patients.
Specifications
BACE2 Chimeric | |
Recombinant Monoclonal | |
1 mg/mL | |
PBS with 0.02% ProClin 300 | |
Q9Y5Z0 | |
BACE2 | |
Human BACE2 244-333. | |
200 μg | |
Primary | |
Human | |
Antibody | |
IgG1 κ |
Immunohistochemistry, Western Blot, Immunocytochemistry | |
1/ 9 | |
Unconjugated | |
BACE2 | |
1110059C24Rik; 56 kDa aspartic-like protease; AEPLC; AI850424; ALP56; ARP1; asp 1; ASP1; ASP21; Aspartic-like protease 56 kDa; Aspartyl protease 1; Bace2; BAE2; be; beta secretase 2; Beta-secretase 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme 2; beta-site amyloid precursor protein cleaving enzyme 2; Beta-site APP cleaving enzyme 2; beta-site APP-cleaving enzyme 2; CDA13; CEAP1; Down region aspartic protease; Down syndrome region aspartic protease; DRAP; memapsin 1; memapsin-1; Membrane-associated aspartic protease 1; theta-secretase; transmembrane aspartic proteinase Asp1; UNQ418/PRO852 | |
Mouse | |
Protein A | |
RUO | |
25825 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction